Orlistat is used to treat obesity and help in weight loss. Orlistat is to be used along with a low-calorie diet and regular physical exercise. Obesity is a common condition associated with excessive body fat, which in turn increases the risk of other health problems such as diabetes, high blood pressure, certain cancers, and heart disease. Intake of more calories than you burn by exercise or daily activities results in obesity.
Orlistat contains Orlistat, which works in the small intestine and stomach and prevents the action of enzymes that break down fat, which is absorbed by the body. Orlistat decreases the absorption of fat from the food you eat. Thus, fat passes through the gut and is excreted in the faeces, which makes the body unable to use fat as a source of energy or convert it into fat tissue. Thereby, Orlistat helps in weight loss.
Take Orlistat as prescribed by your doctor. You are advised to take Orlistat for as long as your doctor has prescribed it for you based on your medical condition. Some people may experience soft stools, sudden bowel motions, flatulence (gas) with or without oily spotting, oily or fatty stools, stomach pain, stool incontinence (involuntary leakage of stools), and runny or liquid stools. Most of these side effects of Orlistat do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor.
If you are allergic to Orlistat or any other medicines, please tell your doctor. Avoid taking Orlistat if you are pregnant or planning for pregnancy, as it may cause fetal harm. It is not known whether Orlistat is excreted in human milk. Therefore, please consult a doctor if you are a breastfeeding woman. Orlistat is not recommended for children below 18 years of age, as the safety and effectiveness were not established. You are advised to take a multivitamin containing fat-soluble vitamins such as A, D, E, and K at bedtime as Orlistat may reduce the absorption of certain vitamins in the body.
The most common side effects of Orlistat are dizziness, loss of appetite, nausea, stomach upset, thoughts of erythema, abdominal pain, and thrush symptoms (see.itzerlandOrlistat is a lipase inhibitor. Lipases are gut enzymes that break down fat from food. Orlistat kills the lipases by blocking their action in the stomach. This kills the lipases, undigested fat, or excreted from the body. The fat that is not digested is called undigested. When the drug leaves the body, it is taken through a bowel movement (intra-ixie line) or a bowel movement together with a low-calorie, low-fat diet. The erythrocyte (phosphate) level is also read as level of 22. The drug is mainly metabolized by the liver, so you will be asked to remove the drug before erythrocytes reach your level. After the drug is eliminated from the body, it is detected as cholestatic liver disease (CLD). CLD is a rare type of liver failure that may occur 6 months or more after stopping Orlistat. CLD may or may not occur, but it is possible to experience side effects like abdominal pain, flatulence, and bowel motions, jerking muscles, or uncontrollable bowel movements. Please consult a doctor if you have CLD as a side effect.
All drugs can affect each other, so it is not known which ones are responsible for which cases. Any affected person is required to provide their doctor with medical history, current medications, and any other non-prescription or prescription medical information. Also, all doctors should be health conscious and fully disclose any allergies, stress, or anxiety before speaking to them about Orlistat. Please be sure to avoid smoking, drinking too much alcohol, or using recreational drugs such as drugs to treat anxiety, depression, and seizures. If you are taking any anti-diabetic medication, please consult your doctor before taking Orlistat. If you are planning for pregnancy or breast-feeding, please consult a doctor before taking Orlistat.
It is mainly metabolized by the liver, so you will be asked to remove the drug before erythrocytes reach your level.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
HealthylifeHealth Care 1 Stopzin 120mg Daily CapsulesProduct/Labeler: Bazaarvoice: Yes
Current price is OTC price Updated: 06/02/2023
Healthylife provides kelteraclot and ketoconazole product information. This information is for general product information and does not replace the advice of a healthcare professional. Always consult your healthcare provider before starting or stopping any medication.
Healthylife provides product information foralli. It is available at no cost to consumers who are unable to purchase it.
Chewable tabletsHealthylife offers chewable or liquid medication for adults and children 12 years and over. Use this product to provide quick and easy contact information for your order.
naltrexone
liraglutide
ziprasidone
trismus
Current price is OTC price Updated: 02/29/2024
In a recent European study, orlistat was reported to have an incidence of adverse events of 6.5% in patients who had never been prescribed it and 1.2% in those who had a previous diagnosis of type 2 diabetes mellitus. In the United States, it has been reported to be used as monotherapy and as adjunctive therapy to reduce the risk of developing cardiovascular disease, particularly type 2 diabetes.
A recent meta-analysis of randomized controlled trials of the effects of orlistat in the treatment of type 2 diabetes found that orlistat significantly reduced the risk of cardiovascular events in people with a history of type 2 diabetes. In addition, orlistat has also been found to have a protective effect against type 2 diabetes by reducing the risk of cardiovascular events in people with type 2 diabetes.
Based on these data, the European Association of Clinical Oncology has concluded that “the clinical benefits of orlistat should be weighed against the potential risks and benefits of the drug for the individual patient and the treatment must be individualized and tailored to the individual patient”.
In the United Kingdom, orlistat has been reported to have a safety profile that differs from that of other anti-diabetic drugs, such as those used for the treatment of type 2 diabetes. In contrast to other diabetes drugs, which have been used for the treatment of type 2 diabetes, orlistat has a well-established safety profile.
In the European experience, orlistat has not been associated with an increased risk of cardiovascular events and gastrointestinal side effects in patients who were treated for more than 2 years. In addition, orlistat has been associated with a lower incidence of side effects of diabetes medications, such as pancreatitis, constipation, diarrhea, and insomnia. These side effects have also been reported in patients receiving orlistat who had not previously been on this drug.
The safety of orlistat has not been evaluated in a randomized controlled trial in patients who have never been treated with a type 2 diabetes drug, such as orlistat. In the current study, orlistat was used as monotherapy and as adjunctive therapy to reduce the risk of developing cardiovascular disease in patients who were treated for more than two years.
For more information, please see the.
The study was designed as a prospective, randomized, placebo-controlled, double-blind, non-interventional observational study. The main outcome measure was the incidence of cardiovascular events and gastrointestinal side effects. The secondary outcome measures were adherence to orlistat in patients who were treated with it for more than two years, cardiovascular events, and gastrointestinal side effects. Participants who met the following criteria were included: 1) age >65 years; 2) who had a diagnosis of type 2 diabetes; and 3) who had a history of type 2 diabetes for more than 2 years.
The study investigators evaluated participants at the time of enrollment and two years after treatment, using a multistage randomization scale. The researchers randomly assigned patients to one of three treatment arms: placebo, orlistat, or orlistat plus a multistage randomization scale, orlistat plus placebo.
Patients who had a baseline cardiovascular event were assigned to receive orlistat for at least one year. If cardiovascular event rates were <1% in participants who were treated with orlistat for at least two years, or if gastrointestinal side effects were the primary endpoint, or if orlistat was not part of the treatment arm, the trial investigators also assigned patients to receive orlistat for a minimum of one year. Participants who had cardiovascular events and those who had gastrointestinal side effects were assigned to receive orlistat for the second year of treatment.
The primary end point was the incidence of cardiovascular events and gastrointestinal side effects. Secondary end points included the incidence of gastrointestinal side effects, changes in body weight, and changes in the waist circumference (SCL-90) at baseline. The trial investigators administered the investigator-administered dose of orlistat in the form of a modified-release tablet to each patient as the first-line treatment of type 2 diabetes.
Participants in the study who were treated with orlistat for more than two years were randomized to one of three treatment groups: placebo, orlistat plus a multistage randomization scale; or orlistat plus placebo. In each group, participants received the dose of orlistat in combination with a multistage randomization scale, orlistat plus placebo.
Orlistat is used to treat obesity (Weight loss) along with a reduced calorie and lower-fat diet in adults (18 years and above).
Orlistat: Anti-obesity drugs
Orlistat works by attaching to the enzymes in your digestive system (lipases) and preventing them from breaking down some of the fat that you’ve consumed during your meal. The fat that is not digested cannot be absorbed and it is removed by your body.
Consult your doctor if you experience:
We strive to ensure that our medication information is accurate, as accurateispershed medication information is our business. We may quote from various occasions such as, “Adjunct '.”, “Intercall on numbers 1, 2, 3, 4, 5, 6,”, "
Stade de France Pharmacy